Youn Jung Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Youn Jung Lee has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Bong-Jo Kim
Department of Psychiatry, Gyeongsang National University School of Medicine, Jinju, Republic of Korea
4 shared publications - Boseok Cha
Department of Psychiatry Gyeongsang National University Hospital Jinju Korea
4 shared publications - Cheol-Soon Lee
Department of Psychiatry, Gyeongsang National University Changwon Hospital, Changwon, Korea
4 shared publications - Dongyun Lee
Department of Psychiatry Gyeongsang National University Changwon Hospital Changwon Korea
4 shared publications - Eunji Lim
Department of Psychiatry Gyeongsang National University School of Medicine Jinju Korea
4 shared publications - Jae-Won Choi
Department of Psychiatry, Gyeongsang National University Hospital, Jinju, Republic of Korea
4 shared publications
Latest Publications
- Open Access
- 1 October 2021
- Published by Korean Academy of Child and Adolescent Psychiatry in Journal of the Korean Academy of Child and Adolescent Psychiatry
- Vol. 32 (4) , 161-169
Association Between Suicide and Drinking Habits in Adolescents
Ji Won Lee, Bong-Jo Kim, Cheol-Soon Lee, Boseok Cha, So-Jin Lee, Dongyun Lee, Jiyeong Seo, Young-Ji Lee, Youn-Jung Lee, Eunji Lim, and Jae-Won Choi. J Korean Acad Child Adolesc Psychiatry 2021;32:161-9. https://doi.org/10.5765/jkacap.210024
- 1 October 2021
- Published by Korean Academy of Child and Adolescent Psychiatry in Journal of the Korean Academy of Child and Adolescent Psychiatry
- Vol. 32 (4) , 161-169
Open AccessAssociation Between Suicide and Drinking Habits in Adolescents
Ji Won Lee, Bong-Jo Kim, Cheol-Soon Lee, Boseok Cha, So-Jin Lee, Dongyun Lee, Jiyeong Seo, Young-Ji Lee, Youn-Jung Lee, Eunji Lim, and Jae-Won Choi. J Korean Acad Child Adolesc Psychiatry 2021;32:161-9. https://doi.org/10.5765/jkacap.210024
- Open Access
- 30 September 2021
- Published by Chronobiology in Medicine in Chronobiology in Medicine
- Vol. 3 (3) , 112-119
The Development and Application of a Resilience-Promoting Program Using Changes in Sleep-Related Habits in Korean Adolescents
Objective: Resilience-promoting program which covers strategies to improve sleep health through modulation of sleep-related habits has been lacking. The authors aimed to develop a resilience-promoting program that incorporates the encouragement of healthy sleep habits. Methods: Fifty-eight adolescents (27 female, 46.6%; aged 13.78±0.82 years) were recruited to test the effectiveness of the program. Dur- ing the first and final sessions, several self-reported questionnaires, including the Connor-Davidson Resilience Scale (CD-RISC), the Smart- phone Addiction Scale–short version (SAS-SV), Hospital Anxiety and Depression Scale (HADS), Composite Scale of Morningness (CSM), In- somnia Severity Index (ISI), and a sleep habit-related questionnaires were administered to the adolescents. After the first session, adolescents were provided with an Actiwatch and were asked to wear the watch to the last session date. Multiple linear regression analyses were used to identify predictors of resilience and sleep quality.Results: The participants’ resilience, morningness, sleep quality, wake after sleep onset (WASO), and wakening frequency during the night changed significantly. Resilience at the last session was related to sleep quality (β=-0.394, p=0.005) at the last session when controlling for age, sex, and morningness. Sleep quality at the last session was related to the mean sun- light exposure time (β=-0.363, p=0.037) at the last session when controlling for age, sex, and WASO during the third week.Conclusion: This study found that four weekly sessions of resilience-promoting program improved resilience, sleep quality including objective actigraphic measures, and morningness. Improved resilience was related to better sleep quality.
- 30 September 2021
- Published by Chronobiology in Medicine in Chronobiology in Medicine
- Vol. 3 (3) , 112-119
Open AccessThe Development and Application of a Resilience-Promoting Program Using Changes in Sleep-Related Habits in Korean Adolescents
Objective: Resilience-promoting program which covers strategies to improve sleep health through modulation of sleep-related habits has been lacking. The authors aimed to develop a resilience-promoting program that incorporates the encouragement of healthy sleep habits. Methods: Fifty-eight adolescents (27 female, 46.6%; aged 13.78±0.82 years) were recruited to test the effectiveness of the program. Dur- ing the first and final sessions, several self-reported questionnaires, including the Connor-Davidson Resilience Scale (CD-RISC), the Smart- phone Addiction Scale–short version (SAS-SV), Hospital Anxiety and Depression Scale (HADS), Composite Scale of Morningness (CSM), In- somnia Severity Index (ISI), and a sleep habit-related questionnaires were administered to the adolescents. After the first session, adolescents were provided with an Actiwatch and were asked to wear the watch to the last session date. Multiple linear regression analyses were used to identify predictors of resilience and sleep quality.Results: The participants’ resilience, morningness, sleep quality, wake after sleep onset (WASO), and wakening frequency during the night changed significantly. Resilience at the last session was related to sleep quality (β=-0.394, p=0.005) at the last session when controlling for age, sex, and morningness. Sleep quality at the last session was related to the mean sun- light exposure time (β=-0.363, p=0.037) at the last session when controlling for age, sex, and WASO during the third week.Conclusion: This study found that four weekly sessions of resilience-promoting program improved resilience, sleep quality including objective actigraphic measures, and morningness. Improved resilience was related to better sleep quality.
- Open Access
- 31 July 2021
- Published by The Korean Association of Psychoanalysis in Psychoanalysis
- Vol. 32 (3) , 107-111
The Relationship of Pre-Clerkship Immature Defense Style in Medical Students with Physician-Patient Interactions
- 31 July 2021
- Published by The Korean Association of Psychoanalysis in Psychoanalysis
- Vol. 32 (3) , 107-111
Open AccessThe Relationship of Pre-Clerkship Immature Defense Style in Medical Students with Physician-Patient Interactions
- Open Access
- 31 May 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (2) , 334-340
The Relationship between Plasma Erythropoietin Levels and Symptoms of Attention Deficit Hyperactivity Disorder
Se-hoon Shim, Yong-Ku Kim, Young Hwangbo, Hee-jung Yoon, Ji Sun Kim, Youn Jung Lee, Young Sup Woo, Won-Myong Bahk. Clin Psychopharmacol Neurosci 2021;19:334-40. https://doi.org/10.9758/cpn.2021.19.2.334
- 31 May 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (2) , 334-340
Open AccessThe Relationship between Plasma Erythropoietin Levels and Symptoms of Attention Deficit Hyperactivity Disorder
Se-hoon Shim, Yong-Ku Kim, Young Hwangbo, Hee-jung Yoon, Ji Sun Kim, Youn Jung Lee, Young Sup Woo, Won-Myong Bahk. Clin Psychopharmacol Neurosci 2021;19:334-40. https://doi.org/10.9758/cpn.2021.19.2.334
- Open Access
- 1 May 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (2) , 243-253
Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
Objective: Many patients with major depressive disorder (MDD) suffer from residual symptoms without achieving remission. However, pharmacologic options for residual symptoms of MDD have been limited. This study aimed to investigate benefit of aripiprazole augmentation in the treatment of residual symptoms in the patients with partially remitted MDD. Methods: We retrospectively analyzed the 8-week medical records of the patients. The enrolled patients did respond to treatment of antidepressant but were not remitted. The range of 17-item Hamilton Depression Rating Scale (HAMD) total score of the subjects were 8 to 15 points. All patients were currently taking antidepressants when they started aripiprazole. The primary endpoint was the mean change of Clinically Useful Depression Outcome Scale (CUDOS). Secondary endpoint measures were HAMD, Clinical Global Impression-severity (CGI-S) scores, Patient Health Questionnaire-15 (PHQ-15), Beck Anxiety Inventory (BAI), Perceived Deficit Questionnaire-depression (PDQ-D), Sheehan Disability Scale (SDS) and General Health Questionnaire/Quality of Life-12 (GHQ/QL-12). Results: A total of 134 medical records were analyzed. The changes of CUDOS, HAMD, CGI-S, BAI, PHQ-15, PDQ-D, SDS and GHQ/QL-12 from baseline to the endpoint were -7.93, -3.29, -0.80, -4.02, -2.05, -4.35, -4.77 and -2.82, respectively (all p < 0.001). At the endpoint, the newly remitted subjects rate by HAMD score criteria were approximately 46%. Conclusion: Our preliminary findings have presented the effectiveness of aripiprazole augmentation for residual symptoms of partially remitted MDD patients in routine practice. This study assures subsequent well-controlled studies of the possibility of generalizing the above promising outcome in the future.
- 1 May 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (2) , 243-253
Open AccessAdditional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
Objective: Many patients with major depressive disorder (MDD) suffer from residual symptoms without achieving remission. However, pharmacologic options for residual symptoms of MDD have been limited. This study aimed to investigate benefit of aripiprazole augmentation in the treatment of residual symptoms in the patients with partially remitted MDD. Methods: We retrospectively analyzed the 8-week medical records of the patients. The enrolled patients did respond to treatment of antidepressant but were not remitted. The range of 17-item Hamilton Depression Rating Scale (HAMD) total score of the subjects were 8 to 15 points. All patients were currently taking antidepressants when they started aripiprazole. The primary endpoint was the mean change of Clinically Useful Depression Outcome Scale (CUDOS). Secondary endpoint measures were HAMD, Clinical Global Impression-severity (CGI-S) scores, Patient Health Questionnaire-15 (PHQ-15), Beck Anxiety Inventory (BAI), Perceived Deficit Questionnaire-depression (PDQ-D), Sheehan Disability Scale (SDS) and General Health Questionnaire/Quality of Life-12 (GHQ/QL-12). Results: A total of 134 medical records were analyzed. The changes of CUDOS, HAMD, CGI-S, BAI, PHQ-15, PDQ-D, SDS and GHQ/QL-12 from baseline to the endpoint were -7.93, -3.29, -0.80, -4.02, -2.05, -4.35, -4.77 and -2.82, respectively (all p < 0.001). At the endpoint, the newly remitted subjects rate by HAMD score criteria were approximately 46%. Conclusion: Our preliminary findings have presented the effectiveness of aripiprazole augmentation for residual symptoms of partially remitted MDD patients in routine practice. This study assures subsequent well-controlled studies of the possibility of generalizing the above promising outcome in the future.
- 12 March 2021
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 23 (5) , 1-7
Understanding the Connection Between the Gut–Brain Axis and Stress/Anxiety Disorders
Purpose of Review We review the association of the microbiota-gut-brain axis and anxiety disorder or stress. Recent Finding The microbiota–gut–brain axis mechanism encompasses a bidirectional relationship between the brain and gastrointestinal organs. Dysregulation of the microbiota–gut–brain axis has been actively revealed in the context of various psychiatric diseases such as neurodevelopmental disorders, schizophrenia, anxiety disorders, and depression. Summary We suggest that onset of anxiety disorders may be correlated with activation of a microbiota–gut–brain mechanism involving the immune system, neurotransmitters, and the hormonal system. By applying a microbiota–gut–brain axis mechanism, the possibility of using gastrointestinal system drugs such as probiotics and antibiotics as treatments for anxiety disorders is a possibility. Although modification of the microbiota–gut–brain axis mechanism has yet to be adopted clinically, it is expected that novel strategies employing this mechanism will be developed and deployed as new treatments not only for anxiety disorders, but also other psychiatric diseases.
- 12 March 2021
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 23 (5) , 1-7
Understanding the Connection Between the Gut–Brain Axis and Stress/Anxiety Disorders
Purpose of Review We review the association of the microbiota-gut-brain axis and anxiety disorder or stress. Recent Finding The microbiota–gut–brain axis mechanism encompasses a bidirectional relationship between the brain and gastrointestinal organs. Dysregulation of the microbiota–gut–brain axis has been actively revealed in the context of various psychiatric diseases such as neurodevelopmental disorders, schizophrenia, anxiety disorders, and depression. Summary We suggest that onset of anxiety disorders may be correlated with activation of a microbiota–gut–brain mechanism involving the immune system, neurotransmitters, and the hormonal system. By applying a microbiota–gut–brain axis mechanism, the possibility of using gastrointestinal system drugs such as probiotics and antibiotics as treatments for anxiety disorders is a possibility. Although modification of the microbiota–gut–brain axis mechanism has yet to be adopted clinically, it is expected that novel strategies employing this mechanism will be developed and deployed as new treatments not only for anxiety disorders, but also other psychiatric diseases.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (11) , e73
Association between Early Spermarche and Suicide Attempts in Boys: the Korea Youth Risk Behavior Web-based Survey
Lee YJ, et al. J Korean Med Sci. 2021 Mar;36(11):e73. https://doi.org/10.3346/jkms.2021.36.e73
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (11) , e73
Open AccessAssociation between Early Spermarche and Suicide Attempts in Boys: the Korea Youth Risk Behavior Web-based Survey
Lee YJ, et al. J Korean Med Sci. 2021 Mar;36(11):e73. https://doi.org/10.3346/jkms.2021.36.e73
- Open Access
- 31 December 2020
- Published by Chronobiology in Medicine in Chronobiology in Medicine
- Vol. 2 (4) , 160-165
Impact of Exposure to Dim Artificial Light at Night during Sleep on Cognitive Function
- 31 December 2020
- Published by Chronobiology in Medicine in Chronobiology in Medicine
- Vol. 2 (4) , 160-165
Open AccessImpact of Exposure to Dim Artificial Light at Night during Sleep on Cognitive Function
- Open Access
- 30 October 2020
- Published by Korean Society for Schizophrenia Research in Korean Journal of Schizophrenia Research
- Vol. 23 (2) , 71-77
Association Study between Serotonin 1A Receptor Gene rs6295 Polymorphism and Tardive Dyskinesia in Patients with Schizophrenia
서 론 조현병 치료에 있어서 항정신병약물은 필수적인 약물 중에 하나로 알려져 있으며 항정신병 약물을 복용하는 환자 중 29~74% 정도에서 추체외로부작용(extrapyramidal symptoms)이 발생한다고 보고되고 있다. 1) 추체외로부작용으로는 급성 근긴장이상(acute dystonia), 정좌불능증(akathisia), 파 킨슨증(parkinsonism)과 지연성 운동이상(tardive dyskinesia)
- 30 October 2020
- Published by Korean Society for Schizophrenia Research in Korean Journal of Schizophrenia Research
- Vol. 23 (2) , 71-77
Open AccessAssociation Study between Serotonin 1A Receptor Gene rs6295 Polymorphism and Tardive Dyskinesia in Patients with Schizophrenia
서 론 조현병 치료에 있어서 항정신병약물은 필수적인 약물 중에 하나로 알려져 있으며 항정신병 약물을 복용하는 환자 중 29~74% 정도에서 추체외로부작용(extrapyramidal symptoms)이 발생한다고 보고되고 있다. 1) 추체외로부작용으로는 급성 근긴장이상(acute dystonia), 정좌불능증(akathisia), 파 킨슨증(parkinsonism)과 지연성 운동이상(tardive dyskinesia)
- Open Access
- 25 October 2020
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 17 (10) , 1031-1036
Association between the IL10 rs1800896 Polymorphism and Tardive Dyskinesia in Schizophrenia
Objective Interleukin-10 (IL-10) is a major immunoregulatory cytokine and its gene plays a fundamental role in anti-inflammatory and immunosuppressive activity. This study aimed to examine the association between the IL10 gene promoter -1082G/A polymorphism (rs1800896) and tardive dyskinesia (TD) in schizophrenia.Methods Two hundred and eighty unrelated Korean schizophrenic patients participated in this study (105 TD and 175 non-TD patients). TD was diagnosed using the Research Diagnostic Criteria for TD and Abnormal Involuntary Movement Scale (AIMS). Genotyping was performed by RT-PCR and high-resolution melting curve analysis.Results The distributions of genotypic frequencies did not differ between patients with and without TD (χ2=4.33, p=0.115). However, allelic frequencies of the two groups were different (χ2=4.45, p=0.035); the A allele frequency was higher in TD. The total AIMS scores of the three genotypes were not different (F=1.33, p=0.266). However, the total AIMS scores of the A allele carrier and the A allele non-carrier were significantly different (t=5.79, p<0.001). Logistic regression analaysis showed that IL10 -1082G/A genotype significantly predicts presence of TD (p=0.045) after adjusting for covariates such as age and treatment duration.Conclusion This finding suggests that the A allele of rs1800896 may be associated with TD development following a low IL-10 function.
- 25 October 2020
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 17 (10) , 1031-1036
Open AccessAssociation between the IL10 rs1800896 Polymorphism and Tardive Dyskinesia in Schizophrenia
Objective Interleukin-10 (IL-10) is a major immunoregulatory cytokine and its gene plays a fundamental role in anti-inflammatory and immunosuppressive activity. This study aimed to examine the association between the IL10 gene promoter -1082G/A polymorphism (rs1800896) and tardive dyskinesia (TD) in schizophrenia.Methods Two hundred and eighty unrelated Korean schizophrenic patients participated in this study (105 TD and 175 non-TD patients). TD was diagnosed using the Research Diagnostic Criteria for TD and Abnormal Involuntary Movement Scale (AIMS). Genotyping was performed by RT-PCR and high-resolution melting curve analysis.Results The distributions of genotypic frequencies did not differ between patients with and without TD (χ2=4.33, p=0.115). However, allelic frequencies of the two groups were different (χ2=4.45, p=0.035); the A allele frequency was higher in TD. The total AIMS scores of the three genotypes were not different (F=1.33, p=0.266). However, the total AIMS scores of the A allele carrier and the A allele non-carrier were significantly different (t=5.79, p<0.001). Logistic regression analaysis showed that IL10 -1082G/A genotype significantly predicts presence of TD (p=0.045) after adjusting for covariates such as age and treatment duration.Conclusion This finding suggests that the A allele of rs1800896 may be associated with TD development following a low IL-10 function.